HOW VENVALO GROUP CREATES VALUE FROM POTENTIAL
We are focused on Creating Value From Potential™for emerging micro-cap companies using our proprietary VVO Methodology™. In every assignment, our primary goal is to achieve a significant increase of the transaction valuation and/or major increase in the stock price and trading volume. The practice of Venture Value Optimization entails carrying out strategic plans that deal with all areas of a business simultaneously, including its structure, finances, and operations. Empirical evidence indicates that the Venvalo group team’s use of VVO MethodologyTM has a noteworthy effect on a company’s capacity to achieve the highest possible value.
BORIS REZNIK
Boris Reznik is the Chairman of Venvalo Group. During his career spanning four decades, Dr. Reznik founded and built technology companies into market leaders, managed high growth, profitable enterprises, successfully worked with Fortune 500 and emerging companies as clients and partners. He has been an investor in multiple technology-based companies and has participated in many public and private fundings and mergers and acquisitions of technology-based companies, ranging from millions to billions.
THOMAS ICHIM
Thomas Ichim is the Chief Scientific Officer of Venvalo Group. Dr. Ichim is a seasoned biotechnology entrepreneur who dedicated over 20 years to launching, growing, and realizing value of multiple biotech companies. When he was eleven years old, his mother was diagnosed with Leukemia. This catalyzed Thomas’ complete dedication to biomedical sciences, with emphasis on practical implementation of advanced therapies. Dr. Ichim is especially renowned for his advances in regenerative medicine and immunotherapy. Dr. Ichim has led both small and large scientific teams, business development, and general executive functions. He has been a Manager, Vice President, as well as President and CEO of emerging biotechnology startups and billion-dollar public enterprises.
Boris Reznik is the Chairman of Venvalo Group. During his career spanning four decades, Dr. Reznik founded and built technology companies into market leaders, managed high growth, profitable enterprises, successfully worked with Fortune 500 and emerging companies as clients and partners. He has been an investor in multiple technology-based companies and has participated in many public and private fundings and mergers and acquisitions of technology-based companies, ranging from millions to billions.
Thomas Ichim is the Chief Scientific Officer of Venvalo Group. Dr. Ichim is a seasoned biotechnology entrepreneur who dedicated over 20 years to launching, growing, and realizing value of multiple biotech companies. When he was eleven years old, his mother was diagnosed with Leukemia. This catalyzed Thomas’ complete dedication to biomedical sciences, with emphasis on practical implementation of advanced therapies. Dr. Ichim is especially renowned for his advances in regenerative medicine and immunotherapy. Dr. Ichim has led both small and large scientific teams, business development, and general executive functions. He has been a Manager, Vice President, as well as President and CEO of emerging biotechnology startups and billion-dollar public enterprises.
WE CREATE, ENHANCE & EXTRACT
Growing out of several venture-based organizations founded in the early to mid-nineties, Venvalo Group was formed to create, enhance, and extract optimal value from emerging and micro-cap companies. Founders bring a wealth of experience and expertise to the new discipline of Venture Value Optimization.
Therapeutic Solutions International is a regenerative medicine and immunotherapy company which was trading around 0.002 per share when Dr.Ichim came on board, initially as consultant, and subsequently as board member. Dr. Ichim secured funding, obtained numerous patents and regulatory clearances, as well as attracted internationally recognized collaborators and advisory board members. As a result the Company experienced over 10000% appreciation in share price, as well as numerous financings.
Dr. Reznik met the CEO of Cytovia Therapeutics in 2020, the two quickly partnered to help the company realize its incredible potential. After we helped the company move its headquarters to Miami in 2021, our participation has increased significantly. Multiple rounds of private financing, helping in negotiation and execution of ISLE SPAC M&A ($369M) agreement, and connecting the company to an investment banker, while working on an IPO. It has been a rewarding journey that is continues to develop.
Medistem (MEDS) Medistem, a company that specializes in the development of technologies pertaining to adult stem cells, faced a considerable decline in the value of its shares, plummeting to a mere 7 cents per share. The company sought to improve its situation by naming Dr. Ichim as the CEO. With our active participation, the company was able to obtain Investigational New Drug approval from the FDA for the initial human use of endometrial stem cells. Under Dr. Ichims’ leadership, Medistem successfully established a robust portfolio of potential candidates, attracted experienced management, and ultimately sold the company to a NYSE traded entity, Intrexon, for $1.35 per share.
Hospira, Inc. (M&A $14.5B) In 2013, Hospira was experiencing difficulties as their stock price remained stagnant at approximately $30. It was during this time that Dr. Reznik had an interaction with their Senior Vice President, which led us to assist with their recently established strategic plan of creating biosimilars. Our contribution eventually resulted in the approval of Hospira’s initial biosimilar and the company’s acquisition by Pfizer at $90 per share in 2016. During a Hospira board meeting, the Senior Vice President credited our thorough engagement for the remarkable 300% appreciation in valuation.
Medistem (MEDS) Medistem, a company that specializes in the development of technologies pertaining to adult stem cells, faced a considerable decline in the value of its shares, plummeting to a mere 7 cents per share. The company sought to improve its situation by naming Dr. Ichim as the CEO. With our active participation, the company was able to obtain Investigational New Drug approval from the FDA for the initial human use of endometrial stem cells. Under Dr. Ichims’ leadership, Medistem successfully established a robust portfolio of potential candidates, attracted experienced management, and ultimately sold the company to a NYSE traded entity, Intrexon, for $1.35 per share.
Hospira, Inc. (M&A $14.5B) In 2013, Hospira was experiencing difficulties as their stock price remained stagnant at approximately $30. It was during this time that Dr. Reznik had an interaction with their Senior Vice President, which led us to assist with their recently established strategic plan of creating biosimilars. Our contribution eventually resulted in the approval of Hospira’s initial biosimilar and the company’s acquisition by Pfizer at $90 per share in 2016. During a Hospira board meeting, the Senior Vice President credited our thorough engagement for the remarkable 300% appreciation in valuation.
Regen BioPharma (RGBP) Regen BioPharma is an oncology and cell therapy company in which Dr. Ichim identified various intellectual property assets that served as the basis for founding the company as a private subsidiary of a public company. Dr. Ichim positioned the company through leading development of preclinical assets to FDA clearance and successful clinical trials. The company, which was subsequently spun off as an independent entity, had a price appreciation of over 5000%.
Apellis Pharmaceuticals (APLS) IPO $689M to $9.1B Dr. Reznik met the CEO of Apellis in 2017, after the company had their IPO, which valued at $689M. We have been working with Apellis on several of their important programs, contributing to incredible successes, leading to corresponding increases in its valuation. We are proud of our substantial contribution which has attained Apellis’ current valuation of $9.1B.
Venture Value Optimization methodologyTM helps Venvalo Group team achieve incredible results for private and public companies in dramatic increase of the transaction valuation and/or major increase in the stock price and trading volume.